Fighting a round with rotavirus Jackson Clarion Ledger, MS - Nov 24, 2008 Worldwide, rotavirus causes 527000 deaths annually for children younger than 5. That's 1600 children each day. RotaTeq, a new vaccine introduced in 2006, ...
Rotavirus Vaccine Linked To Fewer Childhood Hospitalizations eMaxHealth.com, NC - Nov 19, 2008 The rotavirus vaccine, RotaTeq, licensed in 2006, is recommended for infants, with a total of three doses administered orally at ages two months, ...
WHO, CDC to consider rotavirus vaccine Africa Science News Service, Kenya - Nov 24, 2008 Rotateq, produced by Whitehouse Station, New Jersey-based Merck Rotarix, will be sold by London-based Glaxo. Results of trials gauging the efficacy of the ...
Two sides unable to bridge gap Tampabay.com, FL - Nov 24, 2008 "With rotavirus vaccine, (a problem) was found in 100 children, and it was easily picked up," said Offit, director of the Vaccine Education Center at the ...
Rotavirus Vaccine Dramatically Reduces Hospital Visits For ... Medical News Today (press release), UK - Nov 14, 2008 New results presented at the ICAAC/IDSA* congress in Washington show that the pentavalent oral rotavirus vaccine RotaTeq?? reduced hospitalisations and ...
Author Royalties From Autism Book Donated To Autism Research Medical News Today (press release), UK - Nov 7, 2008 An international expert on rotavirus-specific immune responses, Dr. Offit is the co-inventor of the rotavirus vaccine RotaTeq, for which he received the ...
Postępy w dziedzinie szczepień ochronnych w 2007 roku Medycyna Praktyczna, Poland - Nov 20, 2008 Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind ...
Source: Google News
Recent News and Articles on the Keywords: rotavirus vaccine + rotateq + rotavirus Related to the article below (Last Update: 8/7/2008)
Second rotavirus vaccine licensed, recommended for infants AAP News (subscription) - Aug 1, 2008 Two rotavirus vaccine products are now licensed for use in infants in the United States. In April, the Food and Drug Administration licensed RV1 (Rotarix), ...
Check Out New Rotavirus Vaccine Guidance AAFP News Now - Jul 16, 2008 The minimum interval between doses of rotavirus vaccine is four weeks. All doses should be administered by age 8 months. Although rotavirus infection in the ...
Evidence grows for chickenpox and rotavirus vaccines Pulse, UK - Jul 17, 2008 ... the US ? where the RotaTeq vaccine has been licensed and available for use since February 2006 ? shows 18% of stool samples were positive for rotavirus...
Merck Reports Second-Quarter 2008 Financial Results MarketWatch - Jul 21, 2008 Worldwide sales of ROTATEQ (rotavirus vaccine, live, oral, pentavalent), Merck's vaccine to help protect children against rotavirus gastroenteritis and one ...MRK
...and Vytorin sales decline holds back Merck's revenues Pharma Times (subscription), UK - Jul 22, 2008 Sales of the cervical cancer vaccine Gardasil were down 9% to $326 million, while the rotavirus jab RotaTeq climbed 49% to $178 million. ...MRK
Source: Google News
The promise of new rotavirus vaccines - RI Glass, UD Parashar - N Engl J Med, 2006 - click2.nejm.org ... dose, and (like natural rotavirus infections) provides cross-protection against
most other serotypes. By contrast, Rotateq is a pentavalent vaccine based on a ... -
Development of a Pentavalent Rotavirus Vaccine against Prevalent Serotypes of Rotavirus … - PM Heaton, MG Goveia, JM Miller, P Offit, HF Clark - The Journal of Infectious Diseases, 2005 - UChicago Press ... The effect of dose and composition of a pentavalent rotavirus reassortant vaccine
(RotaTeq?) upon efficacy and immunogenicity in healthy infants [abstract 35 ...
Rotavirus vaccines: current prospects and future challenges - RI Glass, UD Parashar, JS Bresee, R Turcios, TK … - The Lancet, 2006 - Elsevier ... These studies are just starting and results could take 2?3 years. Bovine-human
pentavalent reassortant rotavirusvaccine (RotaTeq, Merck). ...
Rotavirus disease and its prevention. - MA Widdowson, JS Bresee, JR Gentsch, RI Glass - Current Opinion in Gastroenterology, 2005 - co-gastroenterology.com ... One vaccine candidate is a pentavalent vaccine (Rotateq, Merck) composed of five
human ... VP4 gene with P1 specificity, all in the parent bovine rotavirus strain. ...
Burden of Rotavirus Disease in European Union Countries. - M Soriano-Gabarr?, J Mrukowicz, T Vesikari, T … - The Pediatric Infectious Disease Journal, 2006 - pidj.org ... human-bovine reassortant G1, G2, G3, G4 and P1A vaccine (RotaTeq?; Merck & Co ... accurate
data describing the epidemiology and burden of rotavirus infections are ...
[CITATION] The effect of dose and composition of a pentavalent rotavirus vaccine (RotaTeq (TM)) upon safety, … T Vesikari, HF Clark, P Offit, F Schodel - 22nd Annual Meeting European Society for Paediatric …, 2004
Source: Google Scholar
Rotateq, an investigational vaccine for rotavirus gastroenteritis
The FDA’s Vaccines and Related Biological Products Advisory Committee gave a positive opinion on the efficacy and safety of Rotateq ( rotavirus vaccine, live, oral, pentavalent ), an investigational vaccine developed to prevent rotavirus gastroenteritis.
Rotavirus gastroenteritis is the most common cause of severe dehydrating diarrhea in infants and young children, causing an estimated 250,000 emergency department visits and 500,000 visits to physicians offices each year in the United States.
Although symptoms vary, those typically associated with rotavirus gastroenteritis include vomiting, fever, abdominal pain and watery diarrhea which can persist for three to nine days.
The severity of rotavirus gastroenteritis ranges from asymptomatic to dehydrating gastroenteritis that can be fatal.
The incidence of rotavirus is similar in developed and developing countries, which suggests that differences in environment ( e.g., clean water, hygiene or sanitation ) do not prevent this disease.
During the first few years of life, a child typically has several rotavirus infections. The highest rates of gastroenteritis are generally in children under two years of age, who are also at the greatest risk for severe disease. Nearly all children will be infected with rotavirus by age five. There are several different serotypes of rotavirus and the prevalence of these serotypes varies by geographic region and can change from season to season. Children gradually develop immunity against different strains of the virus after several infections.
The Advisory Committee also recommended that Merck continue to develop and conduct post-licensure studies to assess the safety and efficacy of Rotateq if it is approved for use.
The Advisory Committee's recommendation was based on data presented from Phase III clinical trials including the Rotavirus Efficacy and Safety Trial ( REST ).
The REST trial was conducted from 2001 to 2004 worldwide.
A total of 70,301 healthy infants 6 to 12 weeks old were enrolled in 11 countries to receive 3 doses of oral rotavirus vaccine or placebo at 4 to 10 week intervals.
Acute gastroenteritis was an episode of forceful vomiting and/or >3 watery or looser-than-normal stools within a 24-hour period and rotavirus antigen detection by electroimmunoassay ( EIA ) with confirmation by PCR (polymerase chain reaction).
The analysis of hospitalization and emergency department ( ED ) visits showed six hospitalizations and 14 ED visits among children who were given the vaccine, a decrease of 95.8% and 93.40%, respectively.
Analysis of study data also showed an 86.6% reduction in work loss for parents.
